<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506922</url>
  </required_header>
  <id_info>
    <org_study_id>ID00-132</org_study_id>
    <nct_id>NCT00506922</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT</brief_title>
  <official_title>Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After Matched-Unrelated Donor Blood and Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      1. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus
      and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context
      of unrelated donor and one antigen mismatched related donor transplantation.

      Secondary Objectives:

        1. To determine safety of escalating doses of pentostatin in combination with tacrolimus
           and methotrexate.

        2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%.

        3. To document blood levels of tacrolimus when combined with pentostatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the study, patients will have blood, urine, bone marrow, and X-ray exams done. These
      exams are done to monitor the results of the transplantation. Blood tests will be done daily
      while patients are hospitalized.

      Patients in this study will receive chemotherapy and/or radiation to treat their malignancy
      and prevent graft rejection. This is given before the infusion of donor cells.

      Patients with myeloid leukemias may receive busulfan by vein (IV) for 4 days and
      cyclophosphamide by vein for 2 days.

      Patients with lymphoid malignancies may receive thiotepa by vein in one dose,
      cyclophosphamide by vein for 2 days, and irradiation for 4 days.

      Other chemotherapy treatments may be used before donor cell infusion.

      IV injections will be given through a previously inserted catheter that extends into the vena
      cava (a large chest vein).

      Patients will be randomly picked (as in the toss of a coin) to receive one of five different
      treatments. This is done to learn the benefit of pentostatin treatment and the appropriate
      dose. Four of the treatments will use different dose schedules of pentostatin. The fifth
      treatment group will receive no pentostatin at all. All patients receive tacrolimus and
      methotrexate.

      Pentostatin will be given by vein in 4 doses during the first month after transplant.
      Tacrolimus (FK506) will be given by vein or mouth for 6 months. Methotrexate will be given by
      vein for 3 doses in the first week after transplant.

      Patients will receive blood and platelet transfusions after the transplant. The number of
      transfusions will depend on how quickly the blood cell counts return to a normal range.

      Patients will remain in the hospital for about 4-6 weeks and in the Houston area for 100 days
      after the transplant.

      This is an investigational study. All of the study drugs are commercially available.
      Pentostatin will not be used for GVHD prevention outside of this study. A total of 150
      patients will take part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Without GVHD at 100 Days</measure>
    <time_frame>100 days</time_frame>
    <description>The primary efficacy endpoint of escalating doses Pentostatin with Tacrolimus + Methotrexate is success, defined to be that the patient is alive, engrafted, and without acute graft-versus-host disease (GVHD) at 100 days.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>No Pentostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: No Pentostatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Pentostatin 0.5 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: Pentostatin 1 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin 1.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4: Pentostatin 1.5 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5: Pentostatin 2 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <description>Given intravenously on days +8, +15, +22 and +30 post transplant:
Group 2 - Pentostatin 0.5 mg/m^2
Group 3 - Pentostatin 1 mg/m^2
Group 4 - Pentostatin 1.5 mg/m^2
Group 5 - Pentostatin 2 mg/m^2</description>
    <arm_group_label>No Pentostatin</arm_group_label>
    <arm_group_label>Pentostatin 0.5</arm_group_label>
    <arm_group_label>Pentostatin 1</arm_group_label>
    <arm_group_label>Pentostatin 1.5</arm_group_label>
    <arm_group_label>Pentostatin 2</arm_group_label>
    <other_name>Nipent</other_name>
    <other_name>Deoxycoformycin</other_name>
    <other_name>DCF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given intravenously from day -2, and will be switched to oral dosing when tolerated.</description>
    <arm_group_label>No Pentostatin</arm_group_label>
    <arm_group_label>Pentostatin 0.5</arm_group_label>
    <arm_group_label>Pentostatin 1</arm_group_label>
    <arm_group_label>Pentostatin 1.5</arm_group_label>
    <arm_group_label>Pentostatin 2</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.</description>
    <arm_group_label>No Pentostatin</arm_group_label>
    <arm_group_label>Pentostatin 0.5</arm_group_label>
    <arm_group_label>Pentostatin 1</arm_group_label>
    <arm_group_label>Pentostatin 1.5</arm_group_label>
    <arm_group_label>Pentostatin 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients receiving allogeneic hematopoietic transplants from an unrelated donor or one
             antigen mismatched related donors.

          2. Patients with AML, ALL, Hodgkin's disease, MDS (including CMML), CML in late chronic
             or accelerated phase or in blast crisis, and lymphoma in first or later relapses.

          3. Patients must have bilirubin &lt; 1.5 mg/dL, DLCO &gt; 50% predicted, LVEF &gt; 45% and
             performance status 0 or 1.

          4. Candidates must have a creatinine level &lt; 1.5 mg/dL or a calculated creatinine
             clearance &gt; 60 ml/min.

        Exclusion Criteria:

          1. HIV seropositivity

          2. Uncontrolled infection

          3. Pregnancy

          4. Candidates should not have received chemotherapy other than hydroxyurea or Gleevec for
             at least 3 weeks prior to treatment. Maintenance therapy with oral chemotherapy is
             acceptable. Treatment day is defined as transplant day +8, which is the date of first
             dose of pentostatin.

          5. Diagnosis of myelofibrosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos de Lima, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>March 1, 2011</results_first_submitted>
  <results_first_submitted_qc>March 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2011</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>GVHD Prevention</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Pentostatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 15, 2000 to July 26, 2007; All recruitment done at UT MD Anderson Cancer Center</recruitment_details>
      <pre_assignment_details>A total of 150 patients were enrolled, and 147 were available for analysis. Two patients assigned to the 1.5 mg/m^2 arm were removed without receiving treatment (due to ineligibility, and poor donor cell collection). A patient assigned to arm 2.0 mg/m^2 withdrew consent before being treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Pentostatin</title>
          <description>Group 1: No Pentostatin</description>
        </group>
        <group group_id="P2">
          <title>Pentostatin 0.5</title>
          <description>Group 2: Pentostatin 0.5 mg/m^2</description>
        </group>
        <group group_id="P3">
          <title>Pentostatin 1</title>
          <description>Group 3: Pentostatin 1 mg/m^2</description>
        </group>
        <group group_id="P4">
          <title>Pentostatin 1.5</title>
          <description>Group 4: Pentostatin 1.5 mg/m^2</description>
        </group>
        <group group_id="P5">
          <title>Pentostatin 2</title>
          <description>Group 5: Pentostatin 2 mg/m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Pentostatin</title>
          <description>Group 1: No Pentostatin</description>
        </group>
        <group group_id="B2">
          <title>Pentostatin 0.5</title>
          <description>Group 2: Pentostatin 0.5 mg/m^2</description>
        </group>
        <group group_id="B3">
          <title>Pentostatin 1</title>
          <description>Group 3: Pentostatin 1 mg/m^2</description>
        </group>
        <group group_id="B4">
          <title>Pentostatin 1.5</title>
          <description>Group 4: Pentostatin 1.5 mg/m^2</description>
        </group>
        <group group_id="B5">
          <title>Pentostatin 2</title>
          <description>Group 5: Pentostatin 2 mg/m^2</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="19"/>
                    <measurement group_id="B2" value="42" spread="23"/>
                    <measurement group_id="B3" value="47" spread="20"/>
                    <measurement group_id="B4" value="50" spread="22"/>
                    <measurement group_id="B5" value="45" spread="32"/>
                    <measurement group_id="B6" value="46.8" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Without GVHD at 100 Days</title>
        <description>The primary efficacy endpoint of escalating doses Pentostatin with Tacrolimus + Methotrexate is success, defined to be that the patient is alive, engrafted, and without acute graft-versus-host disease (GVHD) at 100 days.</description>
        <time_frame>100 days</time_frame>
        <population>All analysis was intention to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Pentostatin</title>
            <description>150 patients were enrolled, 2 patients not treated, 38 patients were Group 1 (no Pentostatin), the remaining Groups 2,3,4 and 5, 110 patients were analysed that received the Pentostatin.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Without GVHD at 100 Days</title>
          <description>The primary efficacy endpoint of escalating doses Pentostatin with Tacrolimus + Methotrexate is success, defined to be that the patient is alive, engrafted, and without acute graft-versus-host disease (GVHD) at 100 days.</description>
          <population>All analysis was intention to treat (ITT).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Pentostatin</title>
          <description>Group 1: No Pentostatin</description>
        </group>
        <group group_id="E2">
          <title>Pentostatin 0.5</title>
          <description>Group 2: Pentostatin 0.5 mg/m^2</description>
        </group>
        <group group_id="E3">
          <title>Pentostatin 1</title>
          <description>Group 3: Pentostatin 1 mg/m^2</description>
        </group>
        <group group_id="E4">
          <title>Pentostatin 1.5</title>
          <description>Group 4: Pentostatin 1.5 mg/m^2</description>
        </group>
        <group group_id="E5">
          <title>Pentostatin 2</title>
          <description>Group 5: Pentostatin 2 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E4" events="27" subjects_affected="27" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>bacterial</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E4" events="38" subjects_affected="38" subjects_at_risk="61"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>parasite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>fungal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TTP/HUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcos de Lima, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-3219</phone>
      <email>bmcmullin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

